These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS. Zhao X; Tian X; Kajigaya S; Cantilena CR; Strickland S; Savani BN; Mohan S; Feng X; Keyvanfar K; Dunavin N; Townsley DM; Dumitriu B; Battiwalla M; Rezvani K; Young NS; Barrett AJ; Ito S Br J Haematol; 2016 Nov; 175(3):427-439. PubMed ID: 27433923 [TBL] [Abstract][Full Text] [Related]
7. Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers. Glass JL; Hassane D; Wouters BJ; Kunimoto H; Avellino R; Garrett-Bakelman FE; Guryanova OA; Bowman R; Redlich S; Intlekofer AM; Meydan C; Qin T; Fall M; Alonso A; Guzman ML; Valk PJM; Thompson CB; Levine R; Elemento O; Delwel R; Melnick A; Figueroa ME Cancer Discov; 2017 Aug; 7(8):868-883. PubMed ID: 28408400 [TBL] [Abstract][Full Text] [Related]
8. Early B-cell factor 3 (EBF3) is a novel tumor suppressor gene with promoter hypermethylation in pediatric acute myeloid leukemia. Tao YF; Xu LX; Lu J; Hu SY; Fang F; Cao L; Xiao PF; Du XJ; Sun LC; Li ZH; Wang NN; Su GH; Li YH; Li G; Zhao H; Li YP; Xu YY; Zhou HT; Wu Y; Jin MF; Liu L; Zhu XM; Ni J; Wang J; Xing F; Zhao WL; Pan J J Exp Clin Cancer Res; 2015 Jan; 34(1):4. PubMed ID: 25609158 [TBL] [Abstract][Full Text] [Related]
9. Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia. Wong JJ; Lau KA; Pinello N; Rasko JE Cancer Sci; 2014 Nov; 105(11):1457-63. PubMed ID: 25220401 [TBL] [Abstract][Full Text] [Related]
10. Hypermethylation of the GATA binding protein 4 (GATA4) promoter in Chinese pediatric acute myeloid leukemia. Tao YF; Fang F; Hu SY; Lu J; Cao L; Zhao WL; Xiao PF; Li ZH; Wang NN; Xu LX; Du XJ; Sun LC; Li YH; Li YP; Xu YY; Ni J; Wang J; Feng X; Pan J BMC Cancer; 2015 Oct; 15():756. PubMed ID: 26490736 [TBL] [Abstract][Full Text] [Related]
11. Profiling of aberrant DNA methylation in acute myeloid leukemia reveals subclasses of CG-rich regions with epigenetic or genetic association. Gebhard C; Glatz D; Schwarzfischer L; Wimmer J; Stasik S; Nuetzel M; Heudobler D; Andreesen R; Ehninger G; Thiede C; Rehli M Leukemia; 2019 Jan; 33(1):26-36. PubMed ID: 29925905 [TBL] [Abstract][Full Text] [Related]
12. Mutations in the DNMT3A DNA methyltransferase in acute myeloid leukemia patients cause both loss and gain of function and differential regulation by protein partners. Sandoval JE; Huang YH; Muise A; Goodell MA; Reich NO J Biol Chem; 2019 Mar; 294(13):4898-4910. PubMed ID: 30705090 [TBL] [Abstract][Full Text] [Related]
13. MN1 overexpression is driven by loss of DNMT3B methylation activity in inv(16) pediatric AML. Larmonie NSD; Arentsen-Peters TCJM; Obulkasim A; Valerio D; Sonneveld E; Danen-van Oorschot AA; de Haas V; Reinhardt D; Zimmermann M; Trka J; Baruchel A; Pieters R; van den Heuvel-Eibrink MM; Zwaan CM; Fornerod M Oncogene; 2018 Jan; 37(1):107-115. PubMed ID: 28892045 [TBL] [Abstract][Full Text] [Related]
15. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing. Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340 [TBL] [Abstract][Full Text] [Related]
16. Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation. Garciaz S; N'guyen Dasi L; Finetti P; Chevalier C; Vernerey J; Poplineau M; Platet N; Audebert S; Pophillat M; Camoin L; Bertucci F; Calmels B; Récher C; Birnbaum D; Chabannon C; Vey N; Duprez E Clin Epigenetics; 2019 Oct; 11(1):141. PubMed ID: 31606046 [TBL] [Abstract][Full Text] [Related]
17. Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML. Mulet-Lazaro R; van Herk S; Erpelinck C; Bindels E; Sanders MA; Vermeulen C; Renkens I; Valk P; Melnick AM; de Ridder J; Rehli M; Gebhard C; Delwel R; Wouters BJ Blood; 2021 Jul; 138(2):160-177. PubMed ID: 33831168 [TBL] [Abstract][Full Text] [Related]
18. DOK6 promoter methylation serves as a potential biomarker affecting prognosis in de novo acute myeloid leukemia. Sun GK; Tang LJ; Zhou JD; Xu ZJ; Yang L; Yuan Q; Ma JC; Liu XH; Lin J; Qian J; Yao DM Cancer Med; 2019 Oct; 8(14):6393-6402. PubMed ID: 31486300 [TBL] [Abstract][Full Text] [Related]
19. tp53-dependent G2 arrest mediator candidate gene, Reprimo, is down-regulated by promoter hypermethylation in pediatric acute myeloid leukemia. Tao YF; Li ZH; Wang NN; Fang F; Xu LX; Pan J Leuk Lymphoma; 2015; 56(10):2931-44. PubMed ID: 25629980 [TBL] [Abstract][Full Text] [Related]
20. Decreased DNA methylation in acute myeloid leukemia patients with DNMT3A mutations and prognostic implications of DNA methylation. Hájková H; Marková J; Haškovec C; Sárová I; Fuchs O; Kostečka A; Cetkovský P; Michalová K; Schwarz J Leuk Res; 2012 Sep; 36(9):1128-33. PubMed ID: 22749068 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]